Search research articles
Contact Us
Filters
Showing results (1-10 of 142) with videos related to
Page
of 15
Sort By:
Current Opinion in Molecular Therapeutics
|
November 7, 2003
Technology evaluation: CpG-7909, Coley
Stéphane Paul
Annals of the Rheumatic Diseases
|
June 16, 2019
Response to: 'Alcohol is not the missing link between <i>Porphyromonas gingivalis</i> related periodontitis and radiologic progression in early Rheumatoid arthritis' by Hillion <i>et al</i>
Hubert Marotte, Stéphane Paul
The New England Journal of Medicine
|
November 16, 2012
Tofacitinib in active ulcerative colitis
Stéphane Paul, Xavier Roblin
Gastroenterology
|
July 10, 2020
The Nightmare Monitoring of JAKinhibs
Stéphane Paul, Xavier Roblin
Alimentary Pharmacology & Therapeutics
|
February 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game
Xavier Roblin, Stéphane Paul, Stéphane Nancey
Alimentary Pharmacology & Therapeutics
|
May 24, 2021
Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply
Xavier Roblin, Stephane Nancey, Stéphane Paul
Frontiers in Immunology
|
November 10, 2018
Harnessing the Induction of CD8<sup>+</sup> T-Cell Responses Through Metabolic Regulation by Pathogen-Recognition-Receptor Triggering in Antigen Presenting Cells
Francesco Nicoli, Stéphane Paul, Victor Appay
The Journal of Rheumatology
|
September 17, 2019
The MRL/lpr Mouse Model: An Important Animal Model for Systemic Sjögren Syndrome and Polyautoimmunity
Martin Killian, Frédéric Batteux, Stéphane Paul
Annals of Internal Medicine
|
March 7, 2018
Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy
Remi Labetoulle, Xavier Roblin, Stéphane Paul
Alimentary Pharmacology & Therapeutics
|
July 31, 2021
Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply
Xavier Roblin, Stephane Nancey, Stéphane Paul
Page
of 15
Search research articles
Search
Showing results (1-10 of 142) with videos related to
Sort By:
Page
of 15
Current Opinion in Molecular Therapeutics
|
November 7, 2003
Technology evaluation: CpG-7909, Coley
Stéphane Paul
Annals of the Rheumatic Diseases
|
June 16, 2019
Response to: 'Alcohol is not the missing link between <i>Porphyromonas gingivalis</i> related periodontitis and radiologic progression in early Rheumatoid arthritis' by Hillion <i>et al</i>
Hubert Marotte, Stéphane Paul
The New England Journal of Medicine
|
November 16, 2012
Tofacitinib in active ulcerative colitis
Stéphane Paul, Xavier Roblin
Gastroenterology
|
July 10, 2020
The Nightmare Monitoring of JAKinhibs
Stéphane Paul, Xavier Roblin
Alimentary Pharmacology & Therapeutics
|
February 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game
Xavier Roblin, Stéphane Paul, Stéphane Nancey
Alimentary Pharmacology & Therapeutics
|
May 24, 2021
Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply
Xavier Roblin, Stephane Nancey, Stéphane Paul
Frontiers in Immunology
|
November 10, 2018
Harnessing the Induction of CD8<sup>+</sup> T-Cell Responses Through Metabolic Regulation by Pathogen-Recognition-Receptor Triggering in Antigen Presenting Cells
Francesco Nicoli, Stéphane Paul, Victor Appay
The Journal of Rheumatology
|
September 17, 2019
The MRL/lpr Mouse Model: An Important Animal Model for Systemic Sjögren Syndrome and Polyautoimmunity
Martin Killian, Frédéric Batteux, Stéphane Paul
Annals of Internal Medicine
|
March 7, 2018
Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy
Remi Labetoulle, Xavier Roblin, Stéphane Paul
Alimentary Pharmacology & Therapeutics
|
July 31, 2021
Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply
Xavier Roblin, Stephane Nancey, Stéphane Paul
Page
of 15